Privacy Policy
Signals Blog

Contributors

Categories

Right Turn: Genes are this season’s hottest trend

In what feels like back-to-back news, the U.S. Food and Drug Administration (FDA) has approved two gene therapies for cancer. The actual announcements happened seven weeks apart, but for patients, manufacturers, investors and shareholders, it’s like Christmas – over...

Right Turn: This is us

If you’ve stumbled upon this blog thinking you will be reading about the attractive and talented cast of the popular 2016 TV show on NBC, I suspect you will be very disappointed. While there is video for you below, you will not see any rippling muscles and you don’t...

BRM2017: State of the regenerative medicine industry

Although new to the field of science communication, Nathan Holwell has been involved in a variety of research during his undergraduate career and now in his graduate career. He has done research in drug delivery, gene delivery, biomaterials and diagnostic devices. His...

Right Turn: Primers on cell therapy regulation

Understanding cell therapy regulation is an essential component of the bench to bedside pipeline. Without approval from a country’s regulator (Health Canada, FDA, EMA, PMDA, etc.), a product cannot be sold to consumers and the millions invested in research and...

Right Turn: Stem cell “gun” for wound healing

It has been said that the pen is mightier than the sword. Where, then, does the gun factor in? I was amazed, last year, when I learned of the “biopen,” a medical device that draws stem cells to repair damaged or worn cartilage and then the cartilage heals itself with...